Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.
Through our recent acquisition of Protagen AG, Oncimmune has expanded its service offering in profiling autoantibodies for the characterisation and prediction of response and adverse events in immuno-oncology and autoimmune diseases.
Mike FisherCommercial Director
Exhibiting at Booth 5
One Nucleus is a membership organisation for international life science and healthcare companies. We are based in Cambridge and London UK, the heart of Europe’s largest life science and healthcare cluster.
Established in 1997, and formerly known as ERBI, One Nucleus is a not-for-profit, membership organisation and located in Cambridge and London – the centre of Europe’s leading life science and healthcare cluster. More than 470 members include pharmaceutical, biotech, medical device and diagnostic companies and associated technical and commercial service providers.
Aline CharpentierHead of Business Development
Oppilotech have developed a high-resolution platform based on systems biology and machine learning to model biological processes in cells. The platform is utilized to identify first-in-class drug targets and to develop novel modes of action drugs modulating the identified targets.The high level of detail allows us to reveal new biology and identify first-in-class non-intuitive drug targets. We initially focused our modelling efforts on E.coli identifying 4 first-in-class antibacterial drug targets and generated active chemical matter against 3 of them. We are now expanding into pathways in human cells allowing us to address a wider range of diseases including cancer (ERK and DNA Damage pathways) and inflammation (cGAS-STING).
Our Business model is to establish:
· Partnerships with Pharma/Biotechs who would like Oppilotech to model pathways they are working on
· Partnerships with Pharma/Biotech who would like access to targets generated from in-house modelling of pathways
· Partnership with Pharma/Biotechs who would like access to early stage drug development programmes developed by Oppilotech on targets identified in-house
· Partnerships on our antibacterial programmes
Oxford Biomedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 430 people.
Andrew LewinVP, Business Development Manufacturing
Aurelie CharpentierManager, Business Development
Jeremy HarropVP, Business Development Product Licensing
OxStem is a drug discovery company, spun-out from the University of Oxford in 2016, with the unique vision of developing small molecule therapeutics that augment repair mechanisms that already exist within the body. OxStem is developing drug candidates that can awaken endogenous cells to repair tissues affected by disease or injury to treat diseases such as Dementia, Heart Failure, Macular Degeneration (the leading cause of blindness in the developed world) and Oncology.
Carolyn PorterChief Business Officer
Pebmond Associates Ltd
Pebmond Associates provides multifaceted board-level advisory, business development and licensing services. Operating in the EU, US and emerging markets we add value to clients by providing solutions for developing and growing pharma companies, including services from a network of trusted partner companies.
PHASTAR work with small and large pharmaceutical and biotechnology companies to provide statistical consulting and to summarise, analyse and report clinical trials. Our top priority is the quality of our work, ensuring we give you the best statistical advice, and analyse your clinical data optimally, getting it right first time. There are lots of different ways to analyse a set of data. We can advise on how to get the most out of your data. Statistics is an art!
We can work with our own internal systems and processes or seamlessly incorporate with your teams. We can manage and deliver whole clinical trial programs, or give you advice on a trial you are planning.
Our vision is to become the supplier of choice for statistics to the pharma and biotech sector, by delivering quality advice and results, on time and on budget.
Edward ClarkSales and Marketing Director
Pneumagen is using its platform technology, GlycoTarge™, to develop glycan targeted carbohydrate binding modules (CBMs) as a new universal therapeutic modality for the treatment of respiratory tract infections (RTIs) and cancer.
Pneumagen’s lead product, Neumifil™, is a first-in-class mCBM40 being developed for the universal treatment of Influenza Virus (IFV) and Respiratory Syncytial Virus (RSV) infections. When administered intranasally in preclinical models, Neumifil™ has demonstrated prevention, treatment and post-exposure prophylaxis of IFV and RSV infections with no observed toxicity. Pneumagen’s mCBM, in development for cancer, isknown as Neumonco™. In vitro data have demonstrated that mCBMs target and enter cancer cells, reducing cell proliferation, migration, metabolism and differentiation. A recent in vivo study demonstrates that Neumonco™ significantly inhibits tumour growth in an orthotopic mouse xenograft model of human ovarian cancer.
Founded in 2016, the Company is a spin-out start-up from the University of St Andrews in Scotland and has access to world-class scientific expertise and capabilities in glycobiology. Please visit www.pneumagen.com for more information.
Random42 Scientific Communication
Exhibiting at Booth 13
Random42 is the global leader in providing digital scientific communication solutions to the pharmaceutical and biotechnology industry. With over 27 years’ experience, we have grown into the largest company within the industry and have won over 185 awards for our high-quality medical animation and scientific storytelling.
Richard GretheCorporate Strategy Director
Rikesh PatelBusiness Development Director
Liam O' SullivanHead of I.T.
Lucy RobertsMarketing Manager
Scottish Development International
Scottish Development International (SDI) is part of Scotland’s main enterprise, innovation and investment agency and works to help international companies find partners in Scotland and Scottish companies develop their business overseas. SDI also works to attract inward investment and knowledge to Scotland in order to help the economy grow.
SDI has a network of offices around the world and provides a wide range of support services covering each phase of international activity, including: business mentoring, market intelligence, business location information and investor aftercare.
The Scottish Life Sciences sector counts more than 700 organisations and 35,000 people with particular strengths in supporting drug discovery and development, regenerative medicine/stem cells, animal health, medical devices, digital health and clinical translational medicine.
To find out more, visit www.sdi.co.uk and www.lifesciencesscotland.com